ClinicalTrials.gg
RecruitingNCT07730164Updated Jul 28, 2026

One-Page Truth-Telling Aid for Cancer Disclosure

An interventional study of One-Page Truth-Telling Aid and Blank Sheet in Neoplams, Physician-Patient Relations and Communication Research, sponsored by Chang Gung University. Recruiting at 1 site in Taiwan. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Chang Gung University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Nov 2025, registered Jul 2026).
  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether a one-page communication aid can improve communication between physicians and patients with cancer during cancer-related truth-telling consultations. The one-page aid is designed to help physicians quickly understand patients' preferences and needs before the consultation.

The main questions it aims to answer are:

  • Does the one-page communication aid improve patients' satisfaction with how cancer-related information is explained?
  • Does the one-page communication aid reduce patients' emotional distress after the consultation?
  • Does the one-page communication aid improve physicians' confidence in communicating cancer-related information?

Researchers will compare patients whose physicians receive the one-page communication aid with patients whose physicians provide usual care with a blank sheet for patients to write down questions. This comparison will help determine whether the one-page aid improves communication, emotional outcomes, and physician confidence.

Participants will:

  • Complete questionnaires before and after the consultation
  • Receive either the one-page communication aid or a blank sheet, depending on their physician's group
  • Complete follow-up questionnaires at 3 months and 6 months after the consultation

Physicians will also complete brief questionnaires about their communication confidence at baseline, 1 week after recruitment of their first enrolled patient, 3 months, and 6 months.

Read the detailed description

Cancer-related truth-telling is an important but challenging part of oncology care. Patients may differ in how much information they want to receive, how they prefer information to be explained, who they want to be present during the discussion, and what questions or concerns they wish to raise. In routine outpatient settings, physicians often have limited time to identify these individual preferences before discussing cancer-related information.

This study will evaluate a One-Page Truth-Telling Aid designed to help physicians quickly understand patients' disclosure preferences and communication needs before the consultation. The aid is completed with patients before the visit and summarizes key information for the physician, including the patient's preferred way of receiving information, preferred communication style, desired content, and questions the patient would like to ask.

This is a two-arm, single-blind, pragmatic clinical trial. Participating physicians will be assigned to either the experimental group or the control group. Patients will be allocated according to the group assignment of their participating physician. Patients in the experimental group will complete the One-Page Truth-Telling Aid before the consultation and will be encouraged to provide it to their physician at the beginning of the visit. Patients in the control group will receive a blank sheet that they may use to write down questions before the consultation.

The study will assess patient-reported truth-telling experiences, emotional distress, and decisional regret, as well as physician-reported communication confidence. Patient assessments will be conducted before the consultation, immediately after the consultation, and at 3 and 6 months after the consultation. Physician assessments will be conducted before the intervention, 1 week after recruitment of their first enrolled patient, and at 3 and 6 months thereafter.

The study is expected to provide evidence on whether a brief, low-burden communication aid can support patient-centered truth-telling in oncology outpatient care and improve communication-related outcomes for both patients and physicians.

02

Conditions studied

  • Neoplams
  • Physician-Patient Relations
  • Communication Research
  • Disclosure
  • Communication About Health Information
  • Preference, Patient

Browse trials for

Keywords

  • Cancer truth-telling; disclosure preferences; physician-patient communication; communication aid; oncology care; psychooncology
03

In context

Patient Preference

114 studies on the registry are indexed under Patient Preference; 28 are open to participants now.

This study's planned enrollment of 400 is above the median of 142 across 53 interventional studies indexed under Patient Preference.

Browse Patient Preference studies →

Lead sponsor

Chang Gung University is the lead sponsor of 66 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

【Physicians】

  • Inclusion Criteria:

    • Physicians who provide clinical care for patients with cancer in participating outpatient departments.
    • Physicians who are involved in cancer-related truth-telling or disclosure consultations.
    • Physicians who are willing to participate and provide .
  • Exclusion Criteria:

    • Physicians who are unable or unwilling to complete study procedures or follow-up assessments.

【Patients】

  • Inclusion Criteria:

    • Patients diagnosed with cancer.
    • Patients who are scheduled to receive cancer-related information from a participating physician, including information about diagnosis, recurrence, , end-of-life status.
    • Patients who are able to communicate in Mandarin Chinese or Taiwanese.
    • Patients who are able to complete questionnaires independently or with assistance from the research assistant.
    • Patients who are willing to participate and provide informed consent.
  • Exclusion Criteria:

    • Patients who are unable to provide informed consent.
    • Patients with severe cognitive impairment, severe physical illness, or emotional distress that prevents participation, as judged by the clinical team or research staff.
    • Patients who are unable to complete the study questionnaires even with assistance.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    One-Page Truth-Telling Aid

    Patients in this arm will receive the One-Page Truth-Telling Aid before the truth-telling consultation. The aid will be completed with the patient before the visit and summarizes the patient's disclosure preferences, communication needs, and questions for the physician. Patients will be encouraged to provide the aid to their participating physician at the beginning of the consultation so that the physician can quickly understand the patient's preferences and tailor communication accordingly.

    Behavioral: One-Page Truth-Telling Aid

  • Active comparator
    Blank Sheet

    Patients in this arm will receive a blank sheet before the truth-telling consultation. The blank sheet may be used to write down questions or concerns the patient would like to discuss with the physician. It does not include structured questions about disclosure preferences or communication needs. Patients will receive usual care and may choose whether to provide the blank sheet to their participating physician during the consultation.

    Behavioral: Blank Sheet

Interventions

  • BehavioralOne-Page Truth-Telling Aid

    The One-Page Truth-Telling Aid is a brief communication aid completed with patients before the consultation. It summarizes patients' disclosure preferences, communication needs, and questions for the physician. Patients are encouraged to provide the aid to their participating physician at the beginning of the consultation to support patient-centered communication.

  • BehavioralBlank Sheet

    The blank sheet is provided to patients before the consultation and may be used to write down questions or concerns. It does not include structured questions about disclosure preferences or communication needs.

06

What researchers measure

Primary outcomes

  1. Patients' Truth-Telling Preferences and Perceptions

    Patients' truth-telling preferences and perceptions of physicians' actual disclosure practices will be assessed using the 43-item Truth-Telling Questionnaire (TTQ-43). The TTQ-43 includes four domains: how to deliver bad news, emotional support, additional information, and setting. Items are scored from 1 to 5, with higher scores indicating stronger preferences expectation at baseline or greater perceived alignment with physician practice at follow-up.

    Time frame: Baseline, immediately after the truth-telling consultation, 3 months post-intervention, and 6 months post-intervention

Secondary outcomes

  1. Patients' Psychological Distress

    Patients' psychological distress will be assessed using the Depression Anxiety Stress Scale-21 (DASS-21). The DASS-21 includes three subscales: depression, anxiety, and stress. Each subscale score ranges from 0 to 42, with higher scores indicating greater symptom severity. Patients' psychological distress will also be assessed using the Distress Thermometer (DT), a single-item distress screening tool. Scores range from 0 to 10, with higher scores indicating greater distress. A score of 4 or higher indicates clinically relevant distress.

    Time frame: Baseline, immediately after the truth-telling consultation, 3 months post-intervention, and 6 months post-intervention

  2. Physicians' Confidence in Communication

    Physicians' confidence in communication with patients with cancer and their families will be assessed using the 21-item Confidence in Communication with Patients questionnaire. Items are scored from 1 to 10, with higher scores indicating greater confidence.

    Time frame: Baseline, 1 week after recruitment of the physician's first enrolled patient, 3 months post-intervention, and 6 months post-intervention

  3. Patients' Decision Regret

    Patients' regret regarding their treatment decisions will be assessed using the Decision Regret Scale (DRS). Scores range from 0 to 100, with higher scores indicating greater decisional regret. A score greater than 25 indicates moderate to high decisional regret.

    Time frame: 3 months post-intervention and 6 months post-intervention

  4. Treatment-Related Adverse Events

    Treatment-related adverse events will be evaluated using the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) based on electronic health record data. Events are graded from 1 to 5, with higher grades indicating more severe adverse events.

    Time frame: 3 months post-intervention and 6 months post-intervention

  5. Medical Expenditure

    Medical expenditure will be estimated using National Health Insurance points recorded in the electronic health record system, based on the local conversion basis in Taiwan.

    Time frame: 6 months post-intervention

  6. Physicians' Perceived Usefulness of the One-Page Truth-Telling Aid

    Physicians' perceived usefulness of the One-Page Truth-Telling Aid will be assessed using a single-item rating scale from 0 to 10, with higher scores indicating greater perceived usefulness.

    Time frame: 1 week after recruitment of the physician's first enrolled patient, 3 months post-intervention, and 6 months post-intervention

  7. Physicians' Willingness to Recommend the One-Page Truth-Telling Aid

    Physicians' willingness to recommend the One-Page Truth-Telling Aid will be assessed using a single-item rating scale from 0 to 10, with higher scores indicating greater willingness to recommend the aid.

    Time frame: 1 week after recruitment of the physician's first enrolled patient, 3 months post-intervention, and 6 months post-intervention

  8. Patients' Trust in the Physician and Satisfaction With the Disclosure Experience

    Patients' trust in the physician and satisfaction with the disclosure experience will be assessed using single-item rating scales from 0 to 10, with higher scores indicating greater trust and satisfaction.

    Time frame: Immediately after the truth-telling consultation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because the dataset contains sensitive clinical and communication-related information from patients with cancer and participating physicians. De-identified aggregate results may be reported in publications.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Apr 2027, 17 months after the start.

Of 24 interventional studies with no phase under Patient Preference, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Jul 28, 2026
StartActual
Nov 27, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Jul 2027
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07730164
Lead sponsor
Chang Gung University
Responsible party
Shih-Ying Chen (Assistant Professor, Chang Gung University) — Principal investigator
First posted
Jul 28, 2026
Start date
Nov 27, 2025
Primary completion
Apr 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jul 28, 2026

Study contacts

Shih-Ying Chen, PhD
Contact
s26871193@cgu.edu.tw
+886-32118800 #5212
Shih-Ying Chen, PhD
principal investigator · Chang Gung University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion